MAMLD1 and 46,XY Disorders of Sex Development

Tsutomu Ogata; Shinichirou Sano; Eiko Nagata; Fumiko Kato; Maki Fukami

doi:10.1055/s-0032-1324725

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2012; 30(05): 410-416
DOI: 10.1055/s-0032-1324725

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

MAMLD1 and 46,XY Disorders of Sex Development

Tsutomu Ogata

¹Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan

,

Shinichirou Sano

¹Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan

,

Eiko Nagata

¹Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan

,

Fumiko Kato

²Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan

,

Maki Fukami

²Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan

› Author Affiliations

Abstract

MAMLD1 (mastermind-like domain containing 1) is a recently discovered causative gene for 46,XY disorders of sex development (DSD), with hypospadias as the salient clinical phenotype. To date, microdeletions involving MAMLD1 have been identified in six patients, and definitive mutations (nonsense and frameshift mutations that are predicted to undergo nonsense mediated mRNA decay [NMD]) have been found in six patients. In addition, specific MAMLD1 cSNP(s) and haplotype may constitute a susceptibility factor for hypospadias. Furthermore, in vitro studies have revealed that (1) the mouse homolog is expressed in fetal Sertoli and Leydig cells around the critical period for sex development; (2) transient Mamld1 knockdown results in significantly reduced testosterone production primarily because of compromised 17α-hydroxylation and Cyp17a1 expression in Murine Leydig tumor cells; (3) MAMLD1 localizes to the nuclear bodies and transactivates the promoter activity of a non-canonical Notch target gene hairy/enhancer of split 3, without demonstrable DNA-binding capacity; and (4) MAMLD1 is regulated by steroidogenic factor 1 (SF1). These findings suggest that the MAMLD1 mutations cause 46,XY DSD primarily because of compromised testosterone production around the critical period for sex development. Further studies will provide useful information for the molecular network involved in fetal testosterone production.

Keywords

MAMLD1 - 46,XY DSD - hypospadias - testosterone

Full Text

References

References
1 Fukami M, Wada Y, Miyabayashi K , et al. CXorf6 is a causative gene for hypospadias. Nat Genet 2006; 38 (12) 1369-1371
2 Hu LJ, Laporte J, Kress W , et al. Deletions in Xq28 in two boys with myotubular myopathy and abnormal genital development define a new contiguous gene syndrome in a 430 kb region. Hum Mol Genet 1996; 5 (1) 139-143
3 Laporte J, Guiraud-Chaumeil C, Vincent MC , et al; ENMC International Consortium on Myotubular Myopathy. European Neuro-Muscular Center. Mutations in the MTM1 gene implicated in X-linked myotubular myopathy. Hum Mol Genet 1997; 6 (9) 1505-1511
4 Bartsch O, Kress W, Wagner A, Seemanova E. The novel contiguous gene syndrome of myotubular myopathy (MTM1), male hypogenitalism and deletion in Xq28:report of the first familial case. Cytogenet Cell Genet 1999; 85 (3–4) 310-314
5 Biancalana V, Caron O, Gallati S , et al. Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum Genet 2003; 112 (2) 135-142
6 Laporte J, Kioschis P, Hu LJ , et al. Cloning and characterization of an alternatively spliced gene in proximal Xq28 deleted in two patients with intersexual genitalia and myotubular myopathy. Genomics 1997; 41 (3) 458-462
7 Ogata T, Laporte J, Fukami M. MAMLD1 (CXorf6): a new gene involved in hypospadias. Horm Res 2009; 71 (5) 245-252
8 Kuzmiak HA, Maquat LE. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med 2006; 12 (7) 306-316
9 Fukami M, Wada Y, Okada M , et al. Mastermind-like domain-containing 1 (MAMLD1 or CXorf6) transactivates the Hes3 promoter, augments testosterone production, and contains the SF1 target sequence. J Biol Chem 2008; 283 (9) 5525-5532
10 Tsai TC, Horinouchi H, Noguchi S , et al. Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism. Neuromuscul Disord 2005; 15 (3) 245-252
11 Kalfa N, Liu B, Klein O , et al. Mutations of CXorf6 are associated with a range of severities of hypospadias. Eur J Endocrinol 2008; 159 (4) 453-458
12 Chen Y, Thai HT, Lundin J , et al. Mutational study of the MAMLD1-gene in hypospadias. Eur J Med Genet 2010; 53 (3) 122-126
13 Brandão MP, Costa EM, Fukami M , et al. MAMLD1 (mastermind-like domain containing 1) homozygous gain-of-function missense mutation causing 46,XX disorder of sex development in a virilized female. Adv Exp Med Biol 2011; 707: 129-131
14 Zitzmann M. The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res 2009; 37: 52-61
15 O'Shaughnessy PJ, Baker PJ, Monteiro A, Cassie S, Bhattacharya S, Fowler PA. Developmental changes in human fetal testicular cell numbers and messenger ribonucleic acid levels during the second trimester. J Clin Endocrinol Metab 2007; 92 (12) 4792-4801
16 Morohashi KI, Omura T. Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. FASEB J 1996; 10 (14) 1569-1577
17 Parker KL, Schimmer BP. Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr Rev 1997; 18 (3) 361-377
18 Nakamura M, Fukami M, Sugawa F, Miyado M, Nonomura K, Ogata T. Mamld1 knockdown reduces testosterone production and Cyp17a1 expression in mouse Leydig tumor cells. PLoS ONE 2011; 6 (4) e19123
19 Panesar NS, Chan KW, Ho CS. Mouse Leydig tumor cells produce C-19 steroids, including testosterone. Steroids 2003; 68 (3) 245-251
20 Ascoli M, Puett D. Gonadotropin binding and stimulation of steroidogenesis in Leydig tumor cells. Proc Natl Acad Sci U S A 1978; 75 (1) 99-102
21 Rebois RV. Establishment of gonadotropin-responsive murine leydig tumor cell line. J Cell Biol 1982; 94 (1) 70-76
22 Achermann JC, Hughes IA. Disorders of sex development. In: Kronenberg HM, Melmed M, Polonsky KS, Larsen PR, , eds. Williams textbook of endocrinology. 11th editions. Philadelphia: Saunders; 2008: 783-848
23 Lin SE, Oyama T, Nagase T, Harigaya K, Kitagawa M. Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling. J Biol Chem 2002; 277 (52) 50612-50620
24 Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002; 22 (21) 7688-7700
25 Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284 (5415) 770-776
26 Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003; 194 (3) 237-255
27 Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006; 124 (5) 973-983
28 Wilson JJ, Kovall RA. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 2006; 124 (5) 985-996
29 Tonon G, Modi S, Wu L , et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003; 33 (2) 208-213
30 Androutsellis-Theotokis A, Leker RR, Soldner F , et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442 (7104) 823-826
31 Ito M, Achermann JC, Jameson JL. A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes. J Biol Chem 2000; 275 (41) 31708-31714